Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia

JJ Castillo; R Garcia-Sanz; E Hatjiharissi; RA Kyle; X Leleu; M McMaster; G Merlini; MC Minnema; E Morra; RG Owen; S Poulain; MJ Stone; C Tam; M Varettoni; MA Dimopoulos; SP Treon; E Kastritis

Journal article

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia

JJ Castillo, R Garcia-Sanz, E Hatjiharissi, RA Kyle, X Leleu, M McMaster, G Merlini, MC Minnema, E Morra, RG Owen, S Poulain, MJ Stone, C Tam, M Varettoni, MA Dimopoulos, SP Treon, E Kastritis

British Journal of Haematology | WILEY | Published : 2016

DOI: 10.1111/bjh.14196

Download PDF

Abstract

The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration an..

View full abstract

University of Melbourne Researchers

Constantine Tam Author

Grants

Awarded by National Cancer Institute

Funding Acknowledgements

JJC received honoraria from Celgene and Pharmacyclics, and research funding from Abbvie, Gilead, Millennium and Pharmacyclics. RGS received honoraria from Bristol-Myers Squibb, Janssen and Takeda and. EH received honoraria from Amgen, Gilead and Janssen. GM received honoraria from GlaxoSmithKline, Janssen and Millennium-Takeda. RGO received honoraria from Celgene, Janssen, Pharmacyclics and Roche, and research funding from Celgene. CT received honoraria and research funding from Janssen and Roche. MAD received honoraria from Amgen, Celgene, Janssen and Novartis. SPT received research funding and/or honoraria from Gilead, Janssen, Onyx and Pharmacyclics. EK received honoraria from Amgen, Janssen and Takeda and. RAK, XL, MM, MCM, EM, SP, MJS, MV have no conflict of interest to disclose.